The DOI matches its Crossref record, with a small difference in title or year.
The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease
Abstract
The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), a multicenter, randomized, double-blind study, tested the efficacy of cholesterol lowering in reducing risk of coronary heart disease (CHD) in 3,806 asymptomatic middle-aged men with primary hypercholesterolemia (type II hyperlipoproteinemia). The treatment group received the bile acid sequestrant cholestyramine resin and the control group received a placebo for an average of 7.4 years. Both groups followed a moderate cholesterol-lowering diet. The cholestyramine group experienced average plasma total and low-density lipoprotein cholesterol (LDL-C) reductions of 13.4% and 20.3%, respectively, which were 8.5% and 12.6% greater reductions than those obtained in the placebo group. The cholestyramine group experienced a 19% reduction in risk (p less than .05) of the primary end point--definite CHD death and/or definite nonfatal myocardial infarction--reflecting a 24% reduction in definite CHD death and a 19% reduction in nonfatal myocardial infarction. The cumulative seven-year incidence of the primary end point was 7% in the cholestyramine group v 8.6% in the placebo group. In addition, the incidence rates for new positive exercise tests, angina, and coronary bypass surgery were reduced by 25%, 20%, and 21%, respectively, in the cholestyramine group. The risk of death from all causes was only slightly and not significantly reduced in the cholestyramine group. The magnitude of this decrease (7%) was less than for CHD end points because of a greater number of violent and accidental deaths in the cholestyramine group. The LRC-CPPT findings show that reducing total cholesterol by lowering LDL-C levels can diminish the incidence of CHD morbidity and mortality in men at high risk for CHD because of raised LDL-C levels. This clinical trial provides strong evidence for a causal role for these lipids in the pathogenesis of CHD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In clinical studies, ezetimibe in monotherapy at 10 mg/day reduces LDL-C in hypercholesterolaemic patients by 15-22% with relatively high interindividual variation [261].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [261]
In the citing paper
“There are no clinically significant effects of age, sex, or race on ezetimibe pharmacokinetics, and no dosage adjustment is necessary in patients with mild hepatic impairment or mild-to-severe renal insufficiency.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [261]
In the citing paper
“Life-threatening liver failure with ezetimibe as monotherapy or in combination with statins is extremely rare.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [261]
In the citing paper
“The addition of ezetimibe to statin therapy does not appear to increase the incidence of elevated CK levels beyond what is noted with statin treatment alone [261].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [261]
In the citing paper
“Ezetimibe is rapidly absorbed and extensively metabolized to pharmacologically active ezetimibe glucuronide.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [261]
In the citing paper
“In clinical trials, bile acid sequestrants have contributed greatly to the demonstration of the efficacy of LDL-C lowering in reducing CV events in hypercholesterolaemic subjects, with a benefit proportional to the degree of LDL-C lowering.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [239]
In the citing paper
“In clinical trials, bile acid sequestrants have contributed greatly to the demonstration of the efficacy of LDL-C lowering in reducing CV events in hypercholesterolaemic subjects, with a benefit proportional to the degree of LDL-C lowering.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [239]
In the citing paper
“A meta-analysis of large-scale clinical trials involving combination therapy with ezetimibe and statins in patients with high-risk conditions such as FH, ACS, and PAD, confirmed the safety of combination therapy and cardiovascular event suppression resulting from its LDL-C-lowering effects667).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [667]
In the citing paper
“orally administered, colesevelam lowers HbA1c 0.5% in diabetes”
Citations
Cited by
Sorted by citations
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Mortality over a Period of 10 Years in Patients with Peripheral Arterial Disease
Criqui, M. H., Langer, R. D., Fronek, A., Feigelson, H. S., Klauber, M. R., McCann, T. J., & Browner, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202063260605 · Cited by 2,579
Design of the Women’s Health Initiative Clinical Trial and Observational Study
The Women’s Health Initiative Study Group (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,580
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,419
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease
de Lorgeril, M., Renaud, S., Salen, P., Monjaud, I., Mamelle, N., Martin, J. L., Guidollet, J., Touboul, P., & Delaye, J. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92580-1 · Cited by 2,122
Cholesterol-lowering effects of dietary fiber: a meta-analysis
Brown, L., Rosner, B., Willett, W. W., & Sacks, F. M. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.1.30 · Cited by 1,857
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759
An Assessment of Clinically Useful Measures of the Consequences of Treatment
Laupacis, A., Sackett, D. L., & Roberts, R. S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182605 · Cited by 1,681
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.013 · Cited by 1,583
Managing Clinical Knowledge for Health Care Improvement
Balas, E. A., & Boren, S. A. (2000) · Yearbook of Medical Informatics · doi:10.1055/s-0038-1637943 · Cited by 1,479
Celermajer, D. S., Sørensen, K. E., Spiegelhalter, D. J., Georgakopoulos, D., Robinson, J. T. C., & Deanfield, J. E. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90305-0 · Cited by 1,354
Pleiotropic Effects of Statins on the Cardiovascular System
Oesterle, A., Laufs, U., & Liao, J. K. (2017) · Circulation Research · doi:10.1161/circresaha.116.308537 · Cited by 1,247
Celermajer, D. S., Sørensen, K. E., Bull, C., Robinson, J. T. C., & Deanfield, J. E. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90141-4 · Cited by 1,228
Anderson, T. J., Grégoire, J., Pearson, G. J., Barry, A. R., Couture, P., Dawes, M., Francis, G. A., Genest, J., Grover, S., Gupta, M., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.510 · Cited by 1,173
The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia
Himmelfarb, J., Stenvinkel, P., Ikizler, T. A., & Hakim, R. M. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00600.x · Cited by 1,179
Hyperlipidemia as a Risk Factor for Cardiovascular Disease
Nelson, R. H. (2012) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2012.11.003 · Cited by 1,142
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Efficacy and Safety of Plant Stanols and Sterols in the Management of Blood Cholesterol Levels
Katan, M., Grundy, S. M., Jones, P. J. H., Law, M., Miettinen, T. A., & Paoletti, R. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.8.965 · Cited by 1,078
Buchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Chávez-Talavera, O., Tailleux, A., Lefebvre, P., & Staels, B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.055 · Cited by 970
Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990) · BMJ · doi:10.1136/bmj.301.6747.309 · Cited by 960
Causal associations between risk factors and common diseases inferred from GWAS summary data
Zhu, Z., Zheng, Z., Zhang, F., Wu, Y., Trzaskowski, M., Maier, R., Robinson, M. R., McGrath, J. J., Visscher, P. M., Wray, N. R., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02317-2 · Cited by 951
Nakamura, H., Arakawa, K., Itakura, H., Kitabatake, A., Goto, Y., Toyota, T., Nakaya, N., Nishimoto, S., Muranaka, M., Yamamoto, A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69472-5 · Cited by 941
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.10.824 · Cited by 918
Weitz, J. I., Byrne, J., Clagett, G. P., Farkouh, M. E., Porter, J. M., Sackett, D. L., Strandness, D. E., & Taylor, L. M. (1996) · Circulation · doi:10.1161/01.cir.94.11.3026 · Cited by 884
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318277d6a0 · Cited by 845
Pekkanen, J., Linn, S., Heiss, G., Suchindran, C. M., Leon, A., Rifkind, B. M., & Tyroler, H. A. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006143222403 · Cited by 821
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
(1998) · Circulation · doi:10.1161/01.cir.97.15.1440 · Cited by 792
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
Impact of left ventricular hypertrophy on survival in end-stage renal disease
Silberberg, J. S., Barré, P. E., Prichard, S. S., & Sniderman, A. D. (1989) · Kidney International · doi:10.1038/ki.1989.192 · Cited by 780
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 781
Endogenous Nitric Oxide Synthase Inhibitor
Miyazaki, H., Matsuoka, H., Cooke, J. P., Usui, M., Ueda, S., Okuda, S., & Imaizumi, T. (1999) · Circulation · doi:10.1161/01.cir.99.9.1141 · Cited by 756
HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia
Oates, J. A., Wood, A. J. J., & Grundy, S. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807073190105 · Cited by 760
Statin-Associated Side Effects
Thompson, P. D., Panza, G. A., Zaleski, A. L., & Taylor, B. A. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.071 · Cited by 776
The National Cholesterol Education Program
Cleeman, J. I. (1989) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30638-3 · Cited by 711
Carlson, L. A., & Rosenhamer, G. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb15891.x · Cited by 685
Statistical validation of intermediate endpoints for chronic diseases
Freedman, L. S., Graubard, B. I., & Schatzkin, A. G. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110204 · Cited by 651
Incorporating variations in the quality of individual randomized trials into meta-analysis
Detsky, A. S., Naylor, C. D., O'Rourke, K., McGeer, A. J., & L'Abbé, K. A. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90085-2 · Cited by 640
Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
Taylor, A. J., Villines, T. C., Stanek, E. J., Devine, P. J., Griffen, L., Miller, M. J., Weissman, N. J., & Turco, M. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907569 · Cited by 638
Stefanick, M. L., Mackey, S., Sheehan, M., Ellsworth, N., Haskell, W. L., & Wood, P. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807023390103 · Cited by 629
Retardation of angiographic progression of coronary artery disease by nifedipine
Lichtlen, P. R., Rafflenbeul, W., Hecker, H., Jost, S., Hugenholtz, P. G., & Deckers, J. W. (1990) · The Lancet · doi:10.1016/0140-6736(90)91121-p · Cited by 610
Prospective Randomized Open Blinded End-point (PROBE) Study. A novel design for intervention trials
Hansson, L., Hedner, T., & Dahlöf, B. (1992) · Blood Pressure · doi:10.3109/08037059209077502 · Cited by 578
McKeown, N. M., Meigs, J. B., Liu, S., Wilson, P. W., & Jacques, P. F. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/76.2.390 · Cited by 574
The evolving role of statins in the management of atherosclerosis
Vaughan, C. J., Gotto, A. M., & Basson, C. T. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00525-2 · Cited by 573
Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus.
Borch‐Johnsen, K., & Kreiner, S. (1987) · BMJ · doi:10.1136/bmj.294.6588.1651 · Cited by 555
GOLDMAN, L., & COOK, E. F. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-6-825 · Cited by 381
Preventing Heart Disease in the 21st Century
McGill, H. C., McMahan, C. A., & Gidding, S. S. (2008) · Circulation · doi:10.1161/circulationaha.107.717033 · Cited by 560
Jellinger, P. S., Smith, D. A., Mehta, A., Ganda, O. P., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
Li-ya, W., & Parhofer, K. G. (2014) · Metabolism · doi:10.1016/j.metabol.2014.08.010 · Cited by 543
Wood, P. D., Stefanick, M. L., Williams, P. T., & Haskell, W. L. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108153250703 · Cited by 520
Claudel, T., Staels, B., & Kuipers, F. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000178994.21828.a7 · Cited by 506
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
Kannel, W. B., Neaton, J. D., Wentworth, D. N., Thomas, H. E., Stamler, J., Hulley, S. B., & Kjelsberg, M. O. (1986) · American Heart Journal · doi:10.1016/0002-8703(86)90481-3 · Cited by 502
Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement
Heber, D., Yip, I., Ashley, J. M., Elashoff, D. A., Elashoff, R. M., & Go, V. L. W. (1999) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.2.231 · Cited by 499
Health and nutritional benefits from lactic acid bacteria
Gilliland, S. E. (1990) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1990.tb04887.x · Cited by 488
Pedersen, T. R., KJEKSHUS, J. K., Pyörälà, K., OLSSON, A. G., Cook, T. J., Musliner, T. A., Tobert, J. A., & Haghfelt, T. H. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00904-1 · Cited by 465
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.07.007 · Cited by 469
Lloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Daly, D. D., DePalma, S. M., Minissian, M. B., Orringer, C. E., & Smith, S. C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.519 · Cited by 459
Triggers, acute risk factors and vulnerable plaques: The lexicon of a new frontier
Muller, J. E., Abela, G. S., Nesto, R. W., & Tofler, G. H. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90772-2 · Cited by 463
Singh, R. B., Rastogi, S. S., Verma, R. K., Laxmi, B. V., Singh, R. B., Ghosh, S., & Niaz, M. A. (1992) · BMJ · doi:10.1136/bmj.304.6833.1015 · Cited by 457
Assmann, G., & Schulte, H. (1988) · American Heart Journal · doi:10.1016/0002-8703(88)90220-7 · Cited by 447
The Epidemiology of Peripheral Arterial Disease: Importance of Identifying the Population at Risk
Criqui, M. H., Denenberg, J. O., Langer, R. D., & Fronek, A. S. (1997) · Vascular Medicine · doi:10.1177/1358863x9700200310 · Cited by 444
Nauck, M., Warnick, G. R., & Rifai, N. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.2.236 · Cited by 442
Cholesterol Reduction Yields Clinical Benefit: Impact of Statin Trials
Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., & Furberg, C. D. (1998) · Circulation · doi:10.1161/01.cir.97.10.946 · Cited by 442
Hyperlipidemia and Coronary Disease
Lacoste, L., Lam, J. Y. T., Hung, J., Letchacovski, G., Solymoss, B., & Waters, D. D. (1995) · Circulation · doi:10.1161/01.cir.92.11.3172 · Cited by 444
Plehn, J. F., Davis, B. R., Sacks, F. M., Rouleau, J. L., Pfeffer, M. A., Bernstein, V., Cuddy, T. E., Moyé, L. A., Piller, L. B., Rutherford, J., et al. (1999) · Circulation · doi:10.1161/01.cir.99.2.216 · Cited by 429
Adams, M. R., Nakagomi, A., KEECH, A. C., Robinson, J. T. C., McCredie, R. J., Bailey, B. P., Freedman, B., & Celermajer, D. S. (1995) · Circulation · doi:10.1161/01.cir.92.8.2127 · Cited by 419
Bile Acids and Metabolic Regulation
Staels, B., & Fonseca, V. A. (2009) · Diabetes Care · doi:10.2337/dc09-s355 · Cited by 451
Soppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 440
Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats
Kasiske, B. L., O’Donnell, M. P., Cleary, M. P., & Keane, W. F. (1988) · Kidney International · doi:10.1038/ki.1988.51 · Cited by 408
Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?
Robinson, J. G., Smith, B., Maheshwari, N., & Schrott, H. G. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.085 · Cited by 409
Myers, G. L., Cooper, G. R., Winn, C., & Smith, S. J. (1989) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30645-0 · Cited by 404
Reduced or modified dietary fat for preventing cardiovascular disease
Hooper, L., Summerbell, C., Thompson, R. L., Sills, D., Roberts, F. G., Moore, H. J., & Smith, G. D. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002137.pub3 · Cited by 399
Isolated Low HDL Cholesterol As a Risk Factor for Coronary Heart Disease Mortality
Goldbourt, U., Yaari, S., & Medalie, J. H. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.1.107 · Cited by 390
Bounds on Treatment Effects from Studies with Imperfect Compliance
Balke, A., & Pearl, J. (1997) · Journal of the American Statistical Association · doi:10.1080/01621459.1997.10474074 · Cited by 564
Hofmann, A. F., & Roda, A. (1984) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34421-7 · Cited by 384
Number needed to screen: development of a statistic for disease screening
Rembold, C. M. (1998) · BMJ · doi:10.1136/bmj.317.7154.307 · Cited by 385
Jenkins, D. J. A., Kendall, C. W. C., Marchie, A., Parker, T. L., Connelly, P. W., Qian, W., Haight, J. S. J., Faulkner, D. A., Vidgen, E., Lapsley, K. G., et al. (2002) · Circulation · doi:10.1161/01.cir.0000028421.91733.20 · Cited by 378
Naylor, C., Chen, E., & Strauss, B. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-11-916 · Cited by 392
Lloyd‐Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Daly, D. D., DePalma, S. M., Minissian, M., Orringer, C. E., & Smith, S. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.745 · Cited by 398
The outcomes movement—Will it get us where we want to go?
Epstein, A. M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007263230410 · Cited by 371
Jensen, T., Borch‐Johnsen, K., Kofoed‐Enevoldsen, A., & Deckert, T. (1987) · Diabetologia · doi:10.1007/bf00274218 · Cited by 364
Molecular Insights and Therapeutic Targets for Diabetic Endothelial Dysfunction
Xu, J., & Zou, M. (2009) · Circulation · doi:10.1161/circulationaha.108.835223 · Cited by 360
Metadata
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1984-01-20
- Volume
- 251
- Issue
- 3
- Pages
- 351
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4248021162
- Cited by
- 2,747
- References
- 0
- Citations by year
- 2026: 18 · 2025: 14 · 2024: 27 · 2023: 19 · 2022: 20 · 2021: 26 · 2020: 17 · 2019: 34 · 2018: 31 · 2017: 33 · 2016: 42 · 2015: 58 · 2014: 51 · 2013: 46 · 2012: 45
- FWCI
- 196.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- cholestyramine, bile acid sequestrants, primary hypercholesterolemia, type II hyperlipoproteinemia, coronary artery disease, LDL cholesterol, total cholesterol, myocardial infarction, coronary heart disease mortality, cholesterol-lowering diet, cardiovascular risk reduction
- MeSH terms
- Adult, Cholesterol, Cholestyramine Resin, Clinical Trials as Topic, Coronary Disease, Double-Blind Method, Humans, Hypercholesterolemia, Lipoproteins, Male, Middle Aged, Mortality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
